Switching targeted therapies for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have HER2-positive breast cancer that has spread to other parts of the body or is advanced.
- You have at least one tumor that can be measured on a scan like CT or MRI.
- You are generally able to care for yourself and are not bedridden more than half the day.
- You have not had a major surgery in the last 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.